Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

Register NOW for our next IPA Journal Club on 23 September! Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies

IPA

NEW JOURNAL CLUB - REGISTER NOW

IPA Journal Club welcomes Dr. Vinay Suresh to present on the article:

Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials

Learning Objectives:

  • Quantify the pooled incidence of Amyloid-Related Imaging Abnormalities (ARIA)-E and ARIA-H associated with anti–amyloid-β immunotherapies.

  • Compare ARIA-E and ARIA-H risk across different anti–amyloid-β monoclonal antibodies.

  • Examine the association between APOE ε4 genotype and ARIA risk

  • Briefly discuss clinical translation: how comparative risk estimates can inform patient selection, counselling, and MRI surveillance.

Dr. Vinay Suresh, MBBS, MSc (c) in Clinical Neuroscience 
Felix Scholar pursuing an MSc in Clinical Neuroscience at the University of Oxford and incoming PhD candidate in Systems Neuroscience at the Cognitive Neuroscience Laboratory in the German Primate Center (DPZ) / Max Planck, and the Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB). 

He received his medical training (MBBS) at King George’s Medical University (KGMU) in India and aspires to specialise in cognitive neurology. His research interests lie in understanding neural information processing and memory, and how these processes are altered in dementia and neurodegenerative disease.


JOURNAL CLUB ORGANIZER:

Robert Madan MD FRCPC
Baycrest, Toronto
IPA Products & Services Committee
Canada

Please don't hesitate to contact the IPA Secretariat with any questions prior to the event.

Acknowledgements

Acadia Pharmaceuticals Axsome Bristol Myers Squibb
Maplight Cerevel Otsuka